An interventional study of PRIMA Bionic Vision System in Dry Age-related Macular Degeneration, sponsored by Science Corporation. Completed at 1 site in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Science Corporation · Not applicable, Interventional, and Treatment
Among 30 studies in Geographic Atrophy with a site in France — 6 open to participants now, 10 under way, 3 of them phase 3. Geographic Atrophy · France.
Among the 30 studies in Geographic Atrophy with a site in France, this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2017, is one of 3 with no phase, and was the 7th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →6 of the 30 studies in Geographic Atrophy with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 16 more countries
Ages 50+
Medical University of Vienna · Sites in France, Austria, Slovenia and 3 more countries
Ages 55–99
Galimedix Therapeutics Inc · Sites in France, United States, Armenia and 5 more countries
Ages 55+
Regeneron Pharmaceuticals · Sites in France, United States, Australia and 8 more countries
Ages 50–85
Gyroscope Therapeutics Limited · Sites in France, United States, Australia and 3 more countries
Ages 55+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2017.
This study's enrollment of 5 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 310 across the 25 interventional studies, 202 across the 5 observational. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 10 most frequent:
Science Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Science Corporation has 3 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
4 of the studies in Geographic Atrophy with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
| NCT06351657Medical University of ViennaPersonalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Geographic Atrophy with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light perception using the implant.
In this study subjects are provided with a PRIMA sub-retinal implant in one eye. A camera integrated in the external components of the implant captures visual information of the environment, this information is processed by a pocket processor and then transmitted via projected IR light onto the implant. The implant received the projected IR light and stimulates the nerve cells of the retina. Interim analysis will be performed at 6 months after implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with recurrent or chronic inflammations or infections are excluded from the study. Specifically, patients with the following disorders are excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRIMA Bionic Vision System
Device: PRIMA Bionic Vision System
The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration. The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 6 months after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 6 weeks after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 3 months after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 12 months after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 18 months after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 24 months after implantation
Elicitation of perception
Elicitation of visual perception by electrical stimulation of the PRIMA implant measured by Octopus Visual Field
Time frame: 36 months after implantation
Visual Acuity
Visual acuity is a measure of the ability of the visual system to distinguish shapes and details of objects at a given distance. This study use the Landolt Ring to measure visual acuity
Time frame: 18, 24 and 36 months after implantation if applicable
Letter Visual Acuity
Visual acuity is a measure of the ability of the visual system to distinguish shapes and details of objects at a given distance. This endpoint use the ETDRS charts to measure visual acuity
Time frame: 48, 60 and 72 month after implantation
Quality of Live measured by IVI
IVI-Impact of Vision Impairment questionnaire (quality of life based on patient reported outcome of functional vision, participation in vision-related daily living activities and emotional well-being)
Time frame: 48, 60 and 72 month after implantation
Plan to share: No
Ran from Nov 2017 to primary completion in Dec 2024, 85 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Science Corporation